O n April 24, 2014, the cobas HPV Test was approved by the US Food and Drug Administration for use as a frst-line primary screening tool in women aged 25 years or older to assess risk of cervical cancer based on the presence of clinically relevant high-risk human papillomavirus (HPV) DNA. It is the frst and only HPV test indicated as the frst-line primary screen for cervical cancer in the United States. Te test simultaneously provides pooled results for high-risk (HR) genotypes 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 ) and individual results for HPV-16 and HPV-18, the highest-risk genotypes.
Te approval was based on the results of the ATHENA trial 1 in which HPV testing and liquid-based cytology were performed in 47,208 women aged 21 years or older during routine cervical screening. Analysis of HPV testing was performed in those women with atypical squamous cells of undetermined signifcance (ASC-US) who underwent colposcopy and had valid HPV tests and cervical biopsy results. Participants had to be not pregnant, willing to undergo colposcopy and biopsy within 12 weeks if required, and could not have received treatment for cervical intraepithelial neoplasia (CIN) in the preceding 12 months. Clinical validation of the test was achieved by determining its performance characteristics for the detection of CIN grade ≥ 2 and CIN grade ≥ 3 and by comparing its performance with that of the Hybrid Capture 2 test, which detects 13 HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) .
Of the total, 1,923 women (4.1%) had ASC-US cytology. Of those, 1,578 (82.3%) underwent colposcopy and had valid HPV tests and cervical biopsy results. Te percentages of women with ASC-US who underwent colposcopy were similar for HR-HPV-positive (86.4%) and HR-HPV-negative women (83.5%). Overall, the mean age was 37.1 years, 23.1% of women were postmenopausal, 4.3% had received the HPV vaccination, and 0.3% were immunocompromised. Most of the patients were nonsmokers, and the racial distribution of the study population refected that of the overall US population.
Te prevalence rates of overall HR-HPV (all 14 genotypes), HPV-16, and HPV-18 detected with the test were 32.6%, 8.2%, and 2.9%, respectively, with the prevalence of each decreasing with increasing age; in the 21-29-year age group, rates were 54.1%, 16.1%, and 5.6%, respectively. Te prevalence of HR-HPV detected with the Hybrid Capture 2 test was 31.5% and also decreased with increasing age; in the 21-29-year age group, the overall HR-HPV rate was 52.3%.
Among women with ASC-US, biopsy-confrmed CIN 1, CIN 2, and CIN 3 were identifed in 10.0%, 2.2%, and 2.9%. No cases of invasive cervical cancer or adenocarcinoma in situ were found. Te prevalence of CIN ≥ 2 was 5.1%, and the prevalence of CIN ≥ 3 was 2.9%. HPV genotype 16 or 18 was detected in 8% of women without CIN, 18% of women with CIN 1, 44% of women with CIN 2, and 61% of women with CIN ≥ 3.
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